Sema3A derived from GBM elicits TAMs (microglial cell) accumulation, and antibody blockage of Sema3A (anti-Sema3A, F11) exhibits notable tumor inhibitory effect through downregulating TAMs recruitment in patient-derived xenograft (PDX) models (38). The gene discussed is SEMA3A; the disease is neoplasm.